Skip to content

Author

J. Schwamborn

We have 3 of 211 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Interpretable gene networks from single-cell foundation models reveal conserved neurogenic dysfunction in Parkinson’s disease

Interpreting large-scale single-cell transcriptomic data remains a major challenge for understanding disease mechanisms. Recent single-cell foundation models learn rich representations of gene relationships across millions of cells, yet methods for translating these embeddings into biologically interpretable gene networks remain limited. Here we present scGENet, a computational framework that constructs context-specific gene interaction networks from foundation model–derived gene embeddings. By fine-tuning pretrained models on transcriptomic data from human midbrain organoids, scGENet generates transcriptome-scale gene modules that capture biologically meaningful cellular programs. Benchmarking across multiple foundation models demonstrates that networks derived from a fine-tuned scGPT brain model show the highest concordance with curated neuronal pathways, Parkinson’s disease (PD) genetic risk loci, and independent patient-derived transcriptional signatures. Applying this framework to human iPSC-derived PD midbrain organoids reveals transcriptional modules associated with neuronal differentiation, synaptic signaling, and cell-cycle regulation. Single-nucleus RNA sequencing further links these programs to altered cellular composition, including reduced dopaminergic neurons, expansion of radial glia–like progenitors, and a dopaminergic neuron subtype expressing SNCA and VGLUT2. Integration with independent human substantia nigra datasets identifies a conserved neurogenic program disrupted across genetic and idiopathic PD. Together, these results establish a generalizable strategy for extracting interpretable gene networks from single-cell foundation models, enabling systematic discovery of disease-relevant molecular programs across diverse tissues and datasets.

Jun Yin, Maya L. Gosztyla, Birkan Gokbag et al. · 0 citations
Review Open access Jul 2026

Brain organoids in Parkinson's disease drug development: Human-specific models for translational discovery.

Parkinson's disease (PD) poses a major unmet therapeutic challenge, with most drug candidates failing in clinical translation despite promising animal model data. Human induced pluripotent stem cell-derived midbrain organoids recapitulate key PD pathological hallmarks - including dopaminergic neuron loss, α-synuclein aggregation, and neuroinflammation - in a genetically defined, human-specific context. This review summarizes drug screening studies in midbrain organoids across genetic, toxin-based, and α-synuclein preformed fibril models. We highlight therapeutic interventions that rescue PD phenotypes, compare organoid and animal model systems, and discuss the personalized medicine potential of patient-derived organoids. We also critically assess current limitations and outline how artificial intelligence integration and assembloid platforms are advancing organoid-based drug discovery towards regulatory acceptance.

Alise Zagare, J. Jarazo, J. Schwamborn · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.